Fmr LLC Arbutus Biopharma Corp Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Fmr LLC holds 100,818 shares of ABUS stock, worth $378,067. This represents 0.0% of its overall portfolio holdings.

Number of Shares

100,818

Previous 165,842 39.21%

Holding current value

$378,067

Previous $427,000 27.17%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.52 - $3.63 $163,860 - $236,037	-65,024 Reduced 39.21%	100,818 $311,000
Q1 2024 May 13, 2024	BUY	$2.26 - $2.92 $1,125 - $1,454	498 Added 0.3%	165,842 $427,000
Q4 2023 Feb 13, 2024	SELL	$1.69 - $2.54 $18,243 - $27,419	-10,795 Reduced 6.13%	165,344 $413,000
Q3 2023 Nov 13, 2023	SELL	$1.9 - $2.27 $16,655 - $19,898	-8,766 Reduced 4.74%	176,139 $357,000
Q2 2023 Aug 11, 2023	SELL	$2.24 - $3.06 $4,058 - $5,544	-1,812 Reduced 0.97%	184,905 $425,000
Q1 2023 May 11, 2023	BUY	$2.23 - $3.1 $3,365 - $4,677	1,509 Added 0.81%	186,717 $565,000
Q4 2022 Feb 13, 2023	SELL	$1.91 - $2.85 $2,994 - $4,468	-1,568 Reduced 0.84%	185,208 $431,000
Q3 2022 Nov 10, 2022	BUY	$1.88 - $2.88 $44,121 - $67,590	23,469 Added 14.37%	186,776 $357,000
Q2 2022 Aug 12, 2022	SELL	$1.98 - $3.17 $1,629 - $2,608	-823 Reduced 0.5%	163,307 $443,000
Q1 2022 May 13, 2022	BUY	$2.42 - $3.98 $397,194 - $653,237	164,130 New	164,130 $489,000
Q3 2021 Nov 15, 2021	SELL	$2.65 - $4.62 $2 - $4	-1 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$2.5 - $3.51 $2 - $3	1 New	1 $0

Others Institutions Holding ABUS

# of Institutions

141

Shares Held

95.7M

Call Options Held

3.44M

Put Options Held

377K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $562M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account